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BACKGROUND: Urinary tract infections (UTIs) are a
common reason for pediatric hospitalizations.
OBJECTIVE: To determine the effect of discordant
antibiotic therapy (in vitro nonsusceptibility of the
uropathogen to initial antibiotic) on clinical outcomes for
children hospitalized for UTI.
DESIGN/SETTING: Multicenter retrospective cohort
study in children aged 3 days to 18 years, hospita-
lized at 5 children’s hospitals with a laboratory-
confirmed UTI. Data were obtained from medical records
and the Pediatric Hospital Information System (PHIS)
database.
PARTICIPANTS: Patients with laboratory-confirmed UTI.
MAIN EXPOSURE: Discordant antibiotic therapy.
MEASUREMENTS: Length of stay and fever duration.
Covariates included age, sex, insurance, race, vesicoureteral
reflux, antibiotic prophylaxis, genitourinary abnormality, and
chronic care conditions.
RESULTS: The median age of the 216 patients was 2.46
years (interquartile range [IQR]: 0.27, 8.89) and 25% were
male. The most common causative organisms were E. coli
and Klebsiella species. Discordant therapy occurred in 10%
of cases and most commonly in cultures positive for Klebsiella
species, Enterobacter species, and mixed organisms. In
adjusted analyses, discordant therapy was associated with a
1.8 day (95% confidence interval [CI]: 1.5, 2.1) longer length of
stay [LOS], but not with fever duration.
CONCLUSIONS: Discordant antibiotic therapy for UTI is
common and associated with longer hospitalizations.
Further research is needed to understand the clinical
factors contributing to the increased LOS and to inform
decisions for empiric antibiotic selection in children with
UTIs. Journal of Hospital Medicine 2012;7:622–627. VC 2012
Society of Hospital Medicine
Urinary tract infections (UTIs) are one of the most
common reasons for pediatric hospitalizations.1 Bacte-
rial infections require prompt treatment with appropri-
ate antimicrobial agents. Results from culture and sus-
ceptibility testing, however, are often unavailable until
48 hours after initial presentation. Therefore, the clini-
cian must select antimicrobials empirically, basing
decisions on likely pathogens and local resistance pat-
terns.2 This decision is challenging because the effect
of treatment delay on clinical outcomes is difficult to
determine and resistance among uropathogens is
increasing. Resistance rates have doubled over the past
several years.3,4 For common first-line antibiotics, such
as ampicillin and trimethoprim-sulfamethoxazole,
resistance rates for Escherichia coli, the most common
uropathogen, exceed 25%.4,5 While resistance to
third-generation cephalosporins remains low, rates in
the United States have increased from <1% in 1999
to 4% in 2010. International data shows much higher
resistance rates for cephalosporins in general.6,7 This
high prevalence of resistance may prompt the use of
broad-spectrum antibiotics for patients with UTI. For
example, the use of third-generation cephalosporins
for UTI has doubled in recent years.3 Untreated, UTIs
can lead to serious illness, but the consequences of
inadequate initial antibiotic coverage are unknown.8,9
Discordant antibiotic therapy, initial antibiotic ther-
apy to which the causative bacterium is not suscepti-
ble, occurs in up to 9% of children hospitalized for
UTI.10 However, there is reason to believe that dis-
cordant therapy may matter less for UTIs than for
infections at other sites. First, in adults hospitalized
with UTIs, discordant initial therapy did not affect the
time to resolution of symptoms.11,12 Second, most
antibiotics used to treat UTIs are renally excreted
and, thus, antibiotic concentrations at the site of
infection are higher than can be achieved in the serum
or cerebrospinal fluid.13 The Clinical and Laboratory
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Standard Institute has acknowledged that traditional
susceptibility breakpoints may be too conservative for
some non-central nervous system infections; such as
non-central nervous system infections caused by Strep-
tococcus pneumoniae.14
As resistance rates increase, more patients are likely
to be treated with discordant therapy. Therefore, we
sought to identify the clinical consequences of discord-




We conducted a multicenter, retrospective cohort
study. Data for this study were originally collected
for a study that determined the accuracy of individual
and combined International Classification of Dis-
eases, Ninth Revision (ICD-9) discharge diagnosis
codes for children with laboratory tests for a UTI, in
order to develop national quality measures for chil-
dren hospitalized with UTIs.15 The institutional
review board for each hospital (Seattle Children’s
Hospital, Seattle, WA; Monroe Carell Jr Children’s
Hospital at Vanderbilt, Nashville, TN; Cincinnati
Children’s Hospital Medical Center, Cincinnati, OH;
Children’s Mercy Hospital, Kansas City, MO; Child-
ren’s Hospital of Philadelphia, Philadelphia, PA)
approved the study.
Data Sources
Data were obtained from the Pediatric Health Infor-
mation System (PHIS) and medical records for
patients at the 5 participating hospitals. PHIS contains
clinical and billing data from hospitalized children at
43 freestanding children’s hospitals. Data quality and
coding reliability are assured through a joint effort
between the Children’s Hospital Association (Shawnee
Mission, KS) and participating hospitals.16 PHIS was
used to identify participants based on presence of dis-
charge diagnosis code and laboratory tests indicating
possible UTI, patient demographics, antibiotic admin-
istration date, and utilization of hospital resources
(length of stay [LOS], laboratory testing).
Medical records for each participant were reviewed
to obtain laboratory and clinical information such as
past medical history (including vesicoureteral reflux
[VUR], abnormal genitourinary [GU] anatomy, use
of prophylactic antibiotic), culture data, and fever
data. Data were entered into a secured centrally
housed web-based data collection system. To assure
consistency of chart review, all investigators respon-
sible for data collection underwent training. In addi-
tion, 2 pilot medical record reviews were performed,
followed by group discussion, to reach consensus
on questions, preselected answers, interpretation of
medical record data, and parameters for free text
data entry.
Subjects
The initial cohort included 460 hospitalized patients,
aged 3 days to 18 years of age, discharged from par-
ticipating hospitals between July 1, 2008 and June 30,
2009 with a positive urine culture at any time during
hospitalization.15 We excluded patients under 3 days
of age because patients this young are more likely to
have been transferred from the birthing hospital for a
complication related to birth or a congenital anomaly.
For this secondary analysis of patients from a prior
study, our target population included patients admit-
ted for management of UTI.15 We excluded patients
with a negative initial urine culture (n ¼ 59) or if
their initial urine culture did not meet definition of
laboratory-confirmed UTI, defined as urine culture
with >50,000 colony-forming units (CFU) with an
abnormal urinalysis (UA) (n ¼ 77).1,17–19 An abnor-
mal UA was defined by presence of white blood cells,
leukocyte esterase, bacteria, and/or nitrites. For our
cohort, all cultures with >50,000 CFU also had an
abnormal urinalysis. We excluded 19 patients with
cultures classified as 10,000–100,000 CFU because we
could not confirm that the CFU was >50,000. We
excluded 30 patients with urine cultures classified as
‘‘normal’’ or ‘‘mixed’’ flora, positive for a mixture of
organisms not further identified, or if results were
unavailable. Additionally, coagulase-negative Staphy-
lococcus species (n ¼ 8) were excluded, as these are
typically considered contaminants in the setting of
urine cultures.2 Patients likely to have received antibi-
otics prior to admission, or develop a UTI after
admission, were identified and removed from the
cohort if they had a urine culture performed more
than 1 day before, or 2 days after, admission (n ¼
35). Cultures without resistance testing to the initial
antibiotic selection were also excluded (n ¼ 16).
Main Outcome Measures
The primary outcome measure was hospital LOS.
Time to fever resolution was a secondary outcome
measure. Fever was defined as temperature 38C.
Fever duration was defined as number of hours until
resolution of fever; only patients with fever at admis-
sion were included in this subanalysis.
Main Exposure
The main exposure was initial antibiotic therapy.
Patients were classified into 3 groups according to ini-
tial antibiotic selection: those receiving 1) concordant;
2) discordant; or 3) delayed initial therapy. Concord-
ance was defined as in vitro susceptibility to the initial
antibiotic or class of antibiotic. If the uropathogen
was sensitive to a narrow-spectrum antibiotic (eg,
first-generation cephalosporin), but was not tested
against a more broad-spectrum antibiotic of the same
class (eg, third-generation cephalosporin), concord-
ance was based on the sensitivity to the narrow-spec-
trum antibiotic. If the uropathogen was sensitive to a
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broad-spectrum antibiotic (eg, third-generation cepha-
losporin), concordance to a more narrow-spectrum
antibiotic was not assumed. Discordance was defined
as laboratory confirmation of in vitro resistance, or in-
termediate sensitivity of the pathogen to the initial an-
tibiotic or class of antibiotics. Patients were consid-
ered to have a delay in antibiotic therapy if they did
not receive antibiotics on the day of, or day after, col-
lection of UA and culture. Patients with more than 1
uropathogen identified in a single culture were classi-
fied as discordant if any of the organisms was discord-
ant to the initial antibiotic; they were classified as
concordant if all organisms were concordant to the
initial antibiotic. Antibiotic susceptibility was not
tested in some cases (n ¼ 16).
Initial antibiotic was defined as the antibiotic(s)
billed on the same day or day after the UA was billed.
If the patient had the UA completed on the day prior
to admission, we used the antibiotic administered on
the day of admission as the initial antibiotic.
Covariates
Covariates were selected a priori to include patient
characteristics likely to affect patient outcomes; all
were included in the final analysis. These were age,
race, sex, insurance, disposition, prophylactic antibi-
otic use for any reason (VUR, oncologic process, etc),
presence of a chronic care condition, and presence of
VUR or GU anatomic abnormality. Age, race, sex,
and insurance were obtained from PHIS. Medical re-
cord review was used to determine prophylactic anti-
biotic use, and presence of VUR or GU abnormalities
(eg, posterior urethral valves). Chronic care conditions
were defined using a previously reported method.20
Data Analysis
Continuous variables were described using median
and interquartile range (IQR). Categorical variables
were described using frequencies. Multivariable analy-
ses were used to determine the independent associa-
tion of discordant antibiotic therapy and the outcomes
of interest. Poisson regression was used to fit the
skewed LOS distribution. The effect of antibiotic con-
cordance or discordance on LOS was determined for
all patients in our sample, as well as for those with a
urine culture positive for a single identified organism.
We used the Kruskal–Wallis test statistic to determine
the association between duration of fever and discord-
ant antibiotic therapy, given that duration of fever is
a continuous variable. Generalized estimating equa-
tions accounted for clustering by hospital and the var-
iability that exists between hospitals.
RESULTS
Of the initial 460 cases with positive urine culture
growth at any time during admission, 216 met inclu-
sion criteria for a laboratory-confirmed UTI from
urine culture completed at admission. The median age
was 2.46 years (IQR: 0.27,8.89). In the study popula-
tion, 25.0% were male, 31.0% were receiving prophy-
lactic antibiotics, 13.0% had any grade of VUR, and
16.7% had abnormal GU anatomy (Table 1). A total
of 82.4% of patients were treated with concordant
initial therapy, 10.2% with discordant initial therapy,
and 7.4% received delayed initial antibiotic therapy.
There were no significant differences between the
groups for any of the covariates. Discordant antibiotic
cases ranged from 4.9% to 21.7% across hospitals.
The most common causative organisms were E. coli
(65.7%) and Klebsiella spp (9.7%) (Table 2). The






N 216 178 (82.4) 22 (10.2) 16 (7.4)
Gender
Male 54 (25.0) 40 (22.5) 8 (36.4) 6 (37.5) 0.18
Female 162 (75.0) 138 (77.5) 14 (63.64) 10 (62.5)
Race
Non-Hispanic white 136 (63.9) 110 (62.5) 15 (71.4) 11 (68.8) 0.83
Non-Hispanic black 28 (13.2) 24 (13.6) 2 (9.5) 2 (12.5)
Hispanic 20 (9.4) 16 (9.1) 3 (14.3) 1 (6.3)
Asian 10 (4.7) 9 (5.1) 1 (4.7)
Other 19 (8.9) 17 (9.7) 2 (12.5)
Payor
Government 97 (44.9) 80 (44.9) 11 (50.0) 6 (37.5) 0.58
Private 70 (32.4) 56 (31.5) 6 (27.3) 8 (50.0)
Other 49 (22.7) 42 (23.6) 5 (22.7) 2 (12.5)
Disposition
Home 204 (94.4) 168 (94.4) 21 (95.5) 15 (93.8) 0.99
Died 1 (0.5) 1 (0.6)
Other 11 (5.1) 9 (5.1) 1 (4.6) 1 (6.3)
Age
3 d–60 d 40 (18.5) 35 (19.7) 3 (13.6) 2 (12.5) 0.53
61 d–2 y 62 (28.7) 54 (30.3) 4 (18.2) 4 (25.0)
3 y–12 y 75 (34.7) 61 (34.3) 8 (36.4) 6 (37.5)
13 y–18 y 39 (18.1) 28 (15.7) 7 (31.8) 4 (25.0)
Length of stay
1 d–5 d 171 (79.2) 147 (82.6) 12 (54.6) 12 (75.0) 0.03
6 d–10 d 24 (11.1) 17 (9.6) 5 (22.7) 2 (12.5)
11 d–15 d 10 (4.6) 5 (2.8) 3 (13.6) 2 (12.5)
16 dþ 11 (5.1) 9 (5.1) 2 (9.1) 0
Complex chronic conditions
Any CCC 94 (43.5) 77 (43.3) 12 (54.6) 5 (31.3) 0.35
Cardiovascular 20 (9.3) 19 (10.7) 1 (6.3) 0.24
Neuromuscular 34 (15.7) 26 (14.6) 7 (31.8) 1 (6.3) 0.06
Respiratory 6 (2.8) 6 (3.4) 0.52
Renal 26 (12.0) 21 (11.8) 4 (18.2) 1 (6.3) 0.52
Gastrointestinal 3 (1.4) 3 (1.7) 0.72
Hematologic/
immunologic
1 (0.5) 1 (4.6) 0.01
Metabolic 8 (3.7) 6 (3.4) 1 (4.6) 1 (6.3) 0.82
Congenital or
genetic
15 (6.9) 11 (6.2) 3 (13.6) 1 (6.3) 0.43
Malignancy 5 (2.3) 3 (1.7) 2 (9.1) 0.08
VUR 28 (13.0) 23 (12.9) 3 (13.6) 2 (12.5) 0.99
Abnormal GU 36 (16.7) 31 (17.4) 4 (18.2) 1 (6.3) 0.51
Prophylactic antibiotics 67 (31.0) 53 (29.8) 10 (45.5) 4 (25.0) 0.28
NOTE: Values listed as number (percentage). Abbreviations: CCC, complex chronic condition; GU, genitou-
rinary; VUR, vesicoureteral reflux. * In vitro susceptibility of uropathogen to initial antibiotic. † In vitro nonsus-
ceptibility of uropathogen to initial antibiotic. ‡ No antibiotics given on day of, or day after, urine culture
collection.
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most common initial antibiotics were a third-genera-
tion cephalosporin (39.1%), combination of ampicillin
and a third- or fourth-generation cephalosporin
(16.7%), and combination of ampicillin with gentami-
cin (11.1%). A third-generation cephalosporin was
the initial antibiotic for 46.1% of the E. coli and
56.9% of Klebsiella spp UTIs. Resistance to third-gen-
eration cephalosporins but carbapenem susceptibility
was noted for 4.5% of E. coli and 7.7% of Klebsiella
spp isolates. Patients with UTIs caused by Klebsiella
spp, mixed organisms, and Enterobacter spp were
more likely to receive discordant antibiotic therapy.
Patients with Enterobacter spp and mixed-organism
UTIs were more likely to have delayed antibiotic ther-
apy. Nineteen patients (8.8%) had positive blood cul-
tures. Fifteen (6.9%) required intensive care unit
(ICU) admission during hospitalization.
Unadjusted results are shown in Supporting Appen-
dix 1, in the online version of this article. In the
adjusted analysis, discordant antibiotic therapy was
associated with a significantly longer LOS, compared
with concordant therapy for all UTIs and for all
UTIs caused by a single organism (Table 3). In
adjusted analysis, discordant therapy was also associ-
ated with a 3.1 day (IQR: 2.0, 4.7) longer length
of stay compared with concordant therapy for all
E. coli UTIs.
Time to fever resolution was analyzed for patients
with a documented fever at presentation for each
treatment subgroup. One hundred thirty-six patients
were febrile at admission and 122 were febrile beyond
the first recorded vital signs. Fever was present at
admission in 60% of the concordant group and 55%
of the discordant group (P ¼ 0.6). The median dura-
tion of fever was 48 hours for the concordant group
(n ¼ 107; IQR: 24, 240) and 78 hours for the dis-
cordant group (n ¼ 12; IQR: 48, 132). All patients
were afebrile at discharge. Differences in fever dura-
tion between treatment groups were not statistically
significant (P ¼ 0.7).
DISCUSSION
Across 5 children’s hospitals, 1 out of every 10 chil-
dren hospitalized for UTI received discordant initial
antibiotic therapy. Children receiving discordant anti-
biotic therapy had a 1.8 day longer LOS when com-
pared with those on concordant therapy. However,
there was no significant difference in time to fever re-
solution between the groups, suggesting that the
increase in LOS was not explained by increased fever
duration.
The overall rate of discordant therapy in this study
is consistent with prior studies, as was the more com-
mon association of discordant therapy with non-E.
coli UTIs.10 According to the Kids’ Inpatient Database
2009, there are 48,100 annual admissions for patients
less than 20 years of age with a discharge diagnosis
code of UTI in the United States.1 This suggests that
nearly 4800 children with UTI could be affected by
discordant therapy annually.
Children treated with discordant antibiotic therapy
had a significantly longer LOS compared to those
treated with concordant therapy. However, differences
in time to fever resolution between the groups were
not statistically significant. While resolution of fever
may suggest clinical improvement and adequate
empiric therapy, the lack of association with antibiotic
concordance was not unexpected, since the relation-
ship between fever resolution, clinical improvement,
and LOS is complex and thus challenging to mea-
sure.21 These results support the notion that fever re-
solution alone may not be an adequate measure of
clinical response.
It is possible that variability in discharge decision-
making may contribute to increased length of stay.
Some clinicians may delay a patient’s discharge until
complete resolution of symptoms or knowledge of sus-
ceptibilities, while others may discharge patients that
are still febrile and/or still receiving empiric antibiot-
ics. Evidence-based guidelines that address the appro-
priate time to discharge a patient with UTI are lack-
ing. The American Academy of Pediatrics provides
recommendations for use of parenteral antibiotics and
hospital admission for patients with UTI, but does not
address discharge decision-making or patient










E. coli 142 129 (90.8) 3 (2.1) 10 (7.0)
Klebsiella spp 21 14 (66.7) 7 (33.3) 0 (0)
Enterococcus spp 12 9 (75.0) 3 (25.0) 0 (0)
Enterobacter spp 10 5 (50.0) 3 (30.0) 2 (20.0)
Pseudomonas spp 10 9 (90.0) 1 (10.0) 0 (0)
Other single organisms 6 5 (83.3) 0 (0) 1 (16.7)
Other identified
multiple organisms
15 7 (46.7) 5 (33.3) 3 (20.0)
Abbreviations: UTI, urinary tract infection. * In vitro susceptibility of uropathogen to initial antibiotic. † In vitro
nonsusceptibility of uropathogen to initial antibiotic. ‡ No antibiotics given on day of, or after, urine culture
collection.
TABLE 3. Difference in LOS for Children With UTI
Based on Empiric Antibiotic Therapy
Bacteria Difference in LOS (95% CI)* P Value
All organisms
Concordant vs discordant 1.8 (2.1, 1.5) <0.0001
Concordant vs delayed antibiotics 1.4 (1.7, 1.1) 0.01
Single organisms
Concordant vs discordant 1.9 (2.4, 1.5) <0.0001
Concordant vs delayed antibiotics 1.2 (1.6, 1.2) 0.37
Abbreviations: CI, confidence interval; LOS, length of stay; UTI, urinary tract infection. * Models adjusted for
age, sex, race, presence of vesicoureteral reflux (VUR), chronic care condition, abnormal genitourinary (GU)
anatomy, prophylactic antibiotic use.
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management in the setting of discordant antibiotic
therapy.2,21
This study must be interpreted in the context of sev-
eral limitations. First, our primary and secondary out-
comes, LOS and fever duration, were surrogate meas-
ures for clinical response. We were not able to measure
all clinical factors that may contribute to LOS, such as
the patient’s ability to tolerate oral fluids and antibiot-
ics. Also, there may have been too few patients to
detect a clinically important difference in fever duration
between the concordant and discordant groups, espe-
cially for individual organisms. Although we did find a
significant difference in LOS between patients treated
with concordant compared with discordant therapy,
there may be residual confounding from unobserved
differences. This confounding, in conjunction with the
small sample size, may cause us to underestimate the
magnitude of the difference in LOS resulting from dis-
cordant therapy. Second, short-term outcomes such as
ICU admission were not investigated in this study;
however, the proportion of patients admitted to the
ICU in our population was quite small, precluding its
use as a meaningful outcome measure. Third, the
potential benefits to patients who were not exposed to
unnecessary antibiotics, or harm to those that were
exposed, could not be measured. Finally, our study was
obtained using data from 5 free-standing tertiary care
pediatric facilities, thereby limiting its generalizability
to other settings. Still, our rates of prophylactic antibi-
otic use, VUR, and GU abnormalities are similar to
others reported in tertiary care children’s hospitals, and
we accounted for these covariates in our model.22–25
As the frequency of infections caused by resistant
bacteria increase, so will the number of patients
receiving discordant antibiotics for UTI, compounding
the challenge of empiric antimicrobial selection. Fur-
ther research is needed to better understand how dis-
cordant initial antibiotic therapy contributes to LOS
and whether it is associated with adverse short- and
long-term clinical outcomes. Such research could also
aid in weighing the risk of broader-spectrum prescrib-
ing on antimicrobial resistance patterns. While we
identified an association between discordant initial an-
tibiotic therapy and LOS, we were unable to deter-
mine the ideal empiric antibiotic therapy for patients
hospitalized with UTI. Further investigation is needed
to inform local and national practice guidelines for
empiric antibiotic selection in patients with UTIs. This
may also be an opportunity to decrease discordant
empiric antibiotic selection, perhaps through use of
antibiograms that stratify patients based on known
factors, to lead to more specific initial therapy.
CONCLUSIONS
This study demonstrates that discordant antibiotic
selection for UTI at admission is associated with
longer hospital stay, but not fever duration. The full
clinical consequences of discordant therapy, and the
effects on length of stay, need to be better understood.
Our findings, taken in combination with careful con-
sideration of patient characteristics and prior history,
may provide an opportunity to improve the hospital
care for patients with UTIs.
Disclosure: Nothing to report.
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